- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Josh Marsh Discusses the Role of Technology, Automation in Patient Assistance Programs
Technology and automation within patient assistance programs can enhance the patient journey and assist pharmaceutical manufacturers at a lower cost, explained Josh Marsh, vice president of Sonexus at Cardinal Health.
Josh Marsh, vice president of Sonexus at Cardinal Health, says that innovations like technology and automation within patient assistance programs can help both patients and manufacturers.
Transcript
How have patient assistance programs in the pharmaceutical industry evolved in recent years?
I've definitely seen a shift over the past 5 to 7 years as a specialty space has grown; more products being launched, more of the patient population being positively impacted by these products coming to the market. I always say that historically, when a brand grew 10%, your patient service program added 10% of new FTEs [full-time equivalents] to the program to support it. Well, that gets very expensive as your brand grows in the market. So, what we've seen is by being able to implement more technology, more automation into the process, we can not only positively impact the patient journey, decreasing that turnaround time, but we're also able to do more for our manufacturers at a lower cost, which is always a goal as well.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
